# US 2021/0280304 A1 · Integrated clinical trial design and design optimization

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0280304 A1
- Document ID: US20210280304A1
- Status: Published application
- Kind: A1
- Application number: 17/194,434
- Filed: 2021-03-08
- Published: 2021-09-09
- Earliest claimed: 2020-03-08
- Inventors: Gen LI
- Web page: https://patentgrep.com/patent/US20210280304A1

## CPC

- G16H 40/20: for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
- G06F 16/258: {Data format conversion from or to a database}
- G16H 10/20: for electronic clinical trials or questionnaires
- G16H 10/60: for patient-specific data, e.g. for electronic patient records
- G16H 50/70: for mining of medical data, e.g. analysing previous cases of other patients
- G16H 70/60: relating to pathologies
- G06F 3/04842: Selection of displayed objects or displayed text elements (G06F3/0482 takes precedence)
- G06F 16/26: Visual data mining; Browsing structured data
- G06Q 10/06375: {Prediction of business process outcome or impact based on a proposed change}
- G06Q 10/10: Office automation; Time management
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G06F: ELECTRIC DIGITAL DATA PROCESSING (computer systems based on specific computational models G06N)
- G06Q: INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR

## Abstract

Clinical trial protocols frequently need to be amended during a clinical trial, but the amendments are costly and can delay new drug approval. It is challenging to avoid, reduce or minimize incidences of amendments. Currently, people have to manually identify flaws of protocol, which is slow and may incur errors due to subjective perspectives and lack of objective, sufficient, and structured data. The present invention discloses an integrated clinical trial design and design optimization platform that efficiently reduces/minimizes incidences of amendments. In one embodiment, the protocol design or optimization is based on data. In one embodiment, the result is more accurate, quantitative and less error-prone; the system can quickly identify flaws; the flaws can be detected at an earlier stage and the system can distinguish key and leading factors and variables, helping sponsors identify the most efficient amendment.

## Claims

### Claim 1

A method for evaluating and amending a protocol of a target clinical trial associated with a disease wherein said protocol has a plurality of parameters each having a value, comprising:
1) obtaining a set of inclusion and exclusion criteria of a target clinical trial associated with a disease;
2) transforming said criteria to a filter for filtering a master database storing patient data in historical clinical trials associated with said disease, generating a subdatabase storing filtered data;
3) constructing a set of baseline characteristics based on said filtered data stored in said subdatabase;
4) conducting a quantitative analysis by comparing said protocol to said set of baseline characteristics; and
5) making a recommendation based on said quantitative analysis; wherein said recommendation comprises one of the following:
a) no protocol amendment is needed if said quantitative analysis indicates that said protocol would achieve one or more objectives of said target clinical trial; and
b) a protocol amendment is needed if said quantitative analysis indicates one of the following:
(1) at least one parameter of said protocol shall be removed or added; and
(2) at least one parameter value of said protocol shall be adjusted,
wherein said protocol amendment would help said target clinical trial achieve one or more objectives according to said quantitative analysis.

### Claim 2 (depends on 1)

The method of claim 1, wherein said set of baseline characteristics comprises all parameters for patient screening in said historical clinical trials.

### Claim 3 (depends on 1)

The method of claim 1, wherein said set of baseline characteristics comprises all key parameters with commonly used values for patient screening in said historical clinical trials.

### Claim 4 (depends on 3)

The method of claim 3, wherein said commonly used values comprise modal values.

### Claim 5 (depends on 1)

The method of claim 1, wherein said quantitative analysis quantifies one or more effects of said target clinical trial caused by an adjustment assuming said adjustment is made.

### Claim 6 (depends on 5)

The method of claim 5, wherein said one or more effects are or associated with one or more of the following:
a) patient enrollment time,
b) number of patients,
c) number of investigator sites,
d) efficiency of enrolling patients at either site or clinical trial level,
e) cost, and
f) a confidence level to achieve any one of a)-e).

### Claim 7 (depends on 6)

The method of claim 6, wherein said efficiency of enrolling patients at site level is characterized by Gross Site Enrollment Rate (GSER), Adjusted Site Enrollment Rate (ASER), or Site Effectiveness Index (SEI), wherein GSER is defined as number of patients enrolled per site per unit of time, ASER is defined as:
A
⁢
S
⁢
E
⁢
R
=
T
⁢
E
∫
i
=
1
N
⁢
(
E
⁢
t
i
-
S
⁢
t
i
)
and SEI is defined as:
SEI
=
∫
i
=
1
N
⁢
(
Et
i
-
St
i
)
(
Et
s
-
St
s
)
×
N
max
,
wherein TE is Total Enrollment, Eti is the time or date the ith site was closed for patient enrollment, and Sti is the time or date the ith site was opened for patient enrollment Nmax is the maximum number of investigator sites opened for enrollment during the patient enrollment, Ets is the time or date the historical clinical trial was closed for patient enrollment, Sts is the time or date the historical clinical trial was opened for patient enrollment.

### Claim 8 (depends on 6)

The method of claim 6, wherein said efficiency of enrolling patients at clinical trial level is characterized by Clinical Trial Enrollment Rate (CTER), wherein CTER is defined as number of patients enrolled per unit of time.

### Claim 9 (depends on 1)

The method of claim 1, wherein said set of baseline characteristics is provided in a table format.

### Claim 10 (depends on 1)

The method of claim 1, wherein said set of baseline characteristics is constructed on a graphical user interface, which allows a user to, in view of importance and priority, add or remove one or more parameters therein.

### Claim 11 (depends on 1)

The method of claim 1, wherein said set of baseline characteristics is constructed on a graphical user interface virtually displaying one or more quantitative analysis results upon selection by a user on said graphical user interface, wherein said one or more quantitative analysis results are from said quantitative analysis.

### Claim 12 (depends on 11)

The method of claim 11, wherein said one or more quantitative results displayed on said graphical user interface comprise a bar chart, a bubble chart or both.

### Claim 13 (depends on 11)

The method of claim 11, wherein said graphical user interface displays a bar chart and a bubble chart, wherein said bar chart profiles values of a selected parameter and frequencies of said values in historical trials, and wherein said bubble chart comprises a plurality of bubbles each representing one clinical trial, and size of bubble reflects enrollment cycle time, wherein when said user selects a value from said values for said selected parameter in said bar chart, the bubble chart highlights all clinical trials with said selected value for said selected parameter.

### Claim 14 (depends on 1)

The method of claim 1, wherein said master database further stores other data from other sources comprising conference abstracts, oral presentations, publications, and regulatory filings.

### Claim 15 (depends on 14)

The method of claim 14, wherein said other data from said other sources is tabulated and stored in a uniform format for data filtering.

### Claim 16 (depends on 1)

The method of claim 1, wherein said one or more objectives comprise one or more of the following:
a) enrollment is completed within a target time;
b) a target number of patients is enrolled,
c) a target number of investigator sites is registered,
d) a target efficiency of enrolling patients at either site or clinical trial level is achieved,
e) a target budget is contained, and
f) a target confidence level to achieve any one of a)-e) is satisfied.

### Claim 17 (depends on 1)

The method of claim 1, wherein, when a protocol amendment is needed, the clinical trial protocol is amended by adjusting a parameter value to modal value in said set of baseline characteristics.

### Claim 18 (depends on 1)

The method of claim 1, wherein, when a protocol amendment is needed, said protocol is amended to achieve a new objective.

### Claim 19 (depends on 18)

The method of claim 18, wherein said new objective is set in view of importance or priority of said target clinical trial from time to time.

### Claim 20 (depends on 1)

The method of claim 1, wherein when a protocol amendment is needed, said protocol is amended in a way that minimum incidences of amendments would be needed.
